Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 5/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | APEX1 | P27695 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4786380 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2TSHREGLN1ITGB1 | |
| SCHEMBL1965772 | 0.95 | — | — | |
| SCHEMBL10067714 | 0.79 | EGLN1 (0.41) | ALDH1A1EGLN1ITGB1ITGA5MAPT | |
| SCHEMBL10630632 | 0.78 | TSHR (0.41) | ALDH1A1SMN1; SMN2TSHREGLN1ITGB1 | |
| SCHEMBL10711707 | 0.78 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRLMNASLC6A5 | |
| SCHEMBL13336065 | 0.77 | CA1 (0.45) | ALDH1A1EGLN1ITGB1ITGA5MAPT | |
| SCHEMBL4804241 | 0.77 | ALDH1A1 (0.39) | ALDH1A1EGLN1ITGB1ITGA5MAPT | |
| SCHEMBL3376460 | 0.77 | ALDH1A1 (0.39) | ALDH1A1EGLN1ITGB1ITGA5MAPT | |
| SCHEMBL4804250 | 0.77 | PTPN1 (0.40) | ALDH1A1EGLN1ITGB1ITGA5MAPT | |
| SCHEMBL2807522 | 0.75 | EGLN1 (0.46) | ALDH1A1EGLN1ITGB1ITGA5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118727156-A | Universal monocrystalline silicon texturing additive, texturing solution containing same, preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-118727156-A | Universal monocrystalline silicon texturing additive, texturing solution containing same, preparation method and application thereof | 浙江奥首材料科技有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-110419477-B | Culture method of macrobrachium rosenbergii seedlings | 苏州市毛氏阳澄湖水产发展有限公司 | 2021-09-17 | — | — | CN | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20020048598-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | MALIK NAVID (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2001041827-A1 | INTERNALLY SUPPORTED BIOMIMETIC MATERIALS AND COATINGS | MALIK NAVID (GB) | 2001-06-14 | — | — | WO | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0998267-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | Malik, Navid (GB) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998056353-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | MALIK NAVID (GB) | 1998-12-17 | — | — | WO | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
| US-5092885-A | Antitumor agents, wouond healing agents, promoters of cell adhesion to prostheses | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-03-03 | — | — | US | disclosed |
| US-5066716-A | Synthesis of chloroacetyl and bromoacetyl modified peptides for the preparation of synthetic peptide polymers, conjugated peptides, and cyclic peptides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1991-11-19 | — | — | US | disclosed |
| US-4786684-A | SOLID PHASE SYNTHESIS | THE MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1988-11-22 | — | — | US | disclosed |
| WO-1988001173-A1 | BENZYLTHIOETHER-LINKED SOLID SUPPORT-BOUND THIOL COMPOUNDS AND METHOD FOR PEPTIDE SYNTHESIS | THE MOUNT SINAI SCHOOL OF MEDICINE (US) | 1988-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020048598-A1 | INTERNALLY SUPPORTED LIPID VESICLE SYSTEMS | STARD3, CHMP4B, EXOSC10 | ALDH1A1 3732/4885SMN1; SMN2 3896/4885TSHR 3247/4885 |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | ALDH1A1 3560/4885SMN1; SMN2 4016/4885TSHR 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.